GD2 and GD3 synthase: novel drug targets for cancer therapy
- Additional Document Info
- View All
Our recent study suggests that targeting GD3 synthase (also known as ST8SIA1)-the rate-limiting enzyme in biosynthesis of the breast cancer stem cell marker GD2-abrogates metastasis and depletes the cancer stem cell populations within a tumor, thus providing an effective therapeutic strategy against metastatic breast cancers.
author list (cited authors)
Sphyris, N., Sarkar, T. R., Battula, V. L., Andreeff, M., & Mani, S. A.